JPRN-UMIN000002628已完成未知
Prospective Study on the effects of cinacalcet HCL on vascular calcification and parathyroid glands size in patients on maintenance hemodialysis - Prospective Study on the effects of cinacalcet HCL on vascular calcification and parathyroid glands size in patients on maintenance hemodialysis
Division of Nephrology and Metabolism, Department of Internal Medicine, Tokai University School of Medicine0 个研究点目标入组 60 人开始时间: 2009年10月14日最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 发起方
- 入组人数
- 60
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Observational
入排标准
- 年龄范围
- 20years-old 至 80years-old（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •(Exclusion criteria that would otherwise affect outcomes) 1. Patients who have received the test drugs within 12 weeks of enrollment 2. Patients who have undergone parathyroidectomy within one year of enrollment 3. Patients who have undergone parathyroid-targeted interventions (intra-parathyroid injection of ethanol, acetic acid, or vitamin D and its derivatives) within 24 weeks of enrollment 4. Patients who have received bisphosphonate products within 12 weeks of enrollment 5. Patients on estrogen replacement therapy 6. Patients receiving elcitonin 7. Patients receiving nicotinamide 8. Patients receiving sodium ferrous citrate (Proprietary name: Ferromia and others) 9. Patients receiving ipriflavone (Proprietary name: Osten and others) 10. Patients receiving vitamin K2 (Proprietary name: Glakay and others) (Exclusion criteria in consideration of safety) 1. Patients with severe gastrointestinal conditions 2. Patients infected with HIV 3. Patients with vasculitis or vascular disorders 4. Patients complicated with severe hepatic dysfunction or cirrhosis 5. Patients complicated with severe cardiac conditions (New York Heart Association Classification, Class III or higher) 6. Patients with uncontrollable diabetes 7. Patients with HbA1c 9% or higher 8. Patients with uncontrollable hypertension 9. Patients unfit for dialysis 10. Patients who are likely prone to severe drug allergy such as anaphylactic shock or who have past or current history of drug or alcohol intoxication 11. Women who are pregnant, lactating or suspected of pregnancy 12. Patients with serious complications such as malignancy and serious infections 13. Patients with any one of the contraindications indicated on the package insert of lanthanum carbonate 14. Patients who are judged unfit as subjects of the study by investigators, sub-investigators or collaborators
研究者
相似试验
已完成
4 期
Efficacy and safety of treatment with Cinacalcet in patients with Primary Hyperparathyroidism due to a MEN-1 mutatioprimary hyperparathyroidismhyperactive parathyroid glands1008362410033949NL-OMON34871eids Universitair Medisch Centrum20
进行中（未招募）
1 期
Study to Investigate Cinacalcet Treatment in Haemodialysis Patients with Secondary Hyperparathyroidism - SENSOREUCTR2004-002310-10-ESAmgen Development Europe800
进行中（未招募）
不适用
Efficacy and safety of the calcimimetic Cinacalcet in the management of patients with Primary Hyperparathyroidism due to a MEN-1 mutation - Cinacalcet in MEN-I PHPTPatients with primary hyperparathyroidism due to a germline mutation in the MEN-1 geneMedDRA version: 12.1Level: LLTClassification code 10036693Term: Primary hyperparathyroidismEUCTR2010-018861-53-NLeiden University Medical Center
已完成
3 期
E.V.O.L.V.E. Trial™: EValuation Of Cinacalcet Hydrochloride (HCl) Therapy to Lower CardioVascular EventsSecondary HyperparathyroidismChronic Kidney DiseaseNCT00345839Amgen3,883
已完成
3 期
EValuation Of Cinacalcet HCL Therapy to Lower CardioVascular Eventsoverlijden (door welke oorzaak dan ook)mortality and cardiovasculair morbidity1001928010029149NL-OMON30733Amgen56